Press Release and Investor Presentation on the Financials and Operational Performance of the Company for the quarter ended June 30, 2026
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 22 Jul 2026, 02:55 PM IST · BSE ID: e092ab90-5064-452b-b003-d2f32ac8fd8e
View Original BSE Filing (PDF)
💡
In Simple Terms
Jubilant Ingrevia announced its first quarter results for FY27, showing increased revenue and profit compared to last year.
🤖 AI Summary
- Jubilant Ingrevia's Q1 FY27 Total Revenue increased 25% YoY to Rs. 1,300 Crore.
- Total EBITDA for Q1 FY27 grew 36% YoY to Rs. 209 Crore, with EBITDA Margin at 16%.
- PAT after Exceptional Items rose 41% YoY to Rs. 106 Crore in Q1 FY27.
- Basic and Diluted EPS for the quarter ended June 30, 2026, was Rs. 6.7.
- The Board approved the financial results for the quarter ended June 30, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Total Revenue
1,300 Rs Crore
25%
Total EBITDA
209 Rs Crore
36%
PAT after Exceptional Items
106 Rs Crore
41%
Basic and Diluted EPS
6.7 Rs.
41%
Specialty Chemicals Segment Revenue
533 Rs Crore
11%
Nutrition & Health Solutions Segment Revenue
243 Rs Crore
36%
Chemical Intermediates Segment Revenue
524 Rs Crore
38%
🏢 How This Affects the Company
The company reported a 15-quarter high revenue, driven by healthy volume growth and improved realizations, especially in Pharmaceuticals and Agrochemicals. Strong traction in the CDMO and Fine Chemicals businesses, alongside growth in Nutrition and Chemical Intermediates, contributed to segment performance.
Consolidated revenue increased to Rs. 1,300 Crore, and PAT after Exceptional Items grew to Rs. 106 Crore, reflecting improved profitability. EBITDA margin increased to 16% from 15% in Q1 FY26, indicating better operational efficiency.
The new Multi-Purpose Plant remains on track for commissioning by the end of the current calendar year, which will strengthen CDMO and Fine Chemicals growth. The company successfully integrated Remidex Pharma and is advancing its Supernova program with new GenAI use cases.
Despite continued geopolitical uncertainties in the Middle East affecting global supply chains, the company's diversified sourcing capabilities and operational agility enabled effective cost pass-through, mitigating supply chain risks.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected as the company's Q1 FY27 financial performance directly impacts its overall valuation and future prospects.
🔍
Management Signal
Management indicates confidence in sustained growth, driven by strategic initiatives and new capacity, and a focus on operational agility.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 results — monitor sequential improvement in revenue and EBITDA.
Progress on new Multi-Purpose Plant commissioning by end of 2026.
Updates on CDMO and Fine Chemicals pipeline expansion and execution.
LOW RISK
The filing indicates strong financial performance and operational resilience despite geopolitical uncertainties.
💡 Investor Takeaway
Jubilant Ingrevia reported Q1 FY27 Total Revenue of Rs. 1,300 Crore, up 25% YoY, and PAT after Exceptional Items of Rs. 106 Crore, up 41% YoY. This confirms strong financial performance and operational execution for the quarter.
⚖️ Strengths & Concerns
✅ Positives
- Total Revenue for Q1 FY27 increased 25% YoY to Rs. 1,300 Crore, reaching a 15-quarter high.
- PAT after Exceptional Items for Q1 FY27 grew 41% YoY to Rs. 106 Crore, indicating strong profit growth.
⚠️ Concerns
- Specialty Chemical Business EBITDA margin decreased to 26% in Q1 FY27 from 27% in Q1 FY26, despite revenue growth.
- The % Share of Overall Revenue for Specialty Chemicals decreased to 41% in Q1 FY27 from 46% in Q1 FY26.
📅 Company Track Record
Jubilant Ingrevia previously reported Q1 FY26 consolidated net profit of Rs. 10582 Lakhs (equivalent to Rs. 105.82 Crore) with a 40.91% YoY increase, as per filings on July 22, 2026. This indicates a consistent growth trend in net profit.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Jubilant Ingrevia's total revenue in Q1 FY27?
Jubilant Ingrevia reported a Total Revenue of Rs. 1,300 Crore for the quarter ended June 30, 2026, which is a 25% increase year-on-year.
How did Jubilant Ingrevia's net profit perform in Q1 FY27?
The Company's PAT after Exceptional Items for Q1 FY27 stood at Rs. 106 Crore, reflecting a 41% increase compared to Q1 FY26.
What was the EBITDA for Jubilant Ingrevia in Q1 FY27?
Total EBITDA for Jubilant Ingrevia in Q1 FY27 was Rs. 209 Crore, representing a 36% year-on-year growth. The EBITDA Margin was 16%.
Which business segments drove growth for Jubilant Ingrevia in Q1 FY27?
Growth in Q1 FY27 was primarily driven by Specialty Chemicals (revenue of Rs. 533 Crore), Nutrition (revenue of Rs. 243 Crore), and Chemical Intermediates (revenue of Rs. 524 Crore).
What is the status of Jubilant Ingrevia's new Multi-Purpose Plant?
The new Multi-Purpose Plant is on track for commissioning by the end of the current calendar year (2026), aimed at strengthening CDMO and Fine Chemicals growth.
Questions based on this BSE filing only. For information purposes.